Every 10-Q that Johnson & Johnson (JNJ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JNJ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JNJ filings page.
Johnson & Johnson reported solid top-line growth for the fiscal second quarter ended June 28, 2026. Sales to customers were $25,310 million, up from $23,743 million, and fiscal six‑month sales were $49,372 million versus $45,636 million, reflecting broad-based increases across Innovative Medicine and MedTech.
Quarterly net earnings were $5,534 million, similar to $5,537 million a year earlier, while six‑month net earnings declined to $10,769 million from $16,536 million, largely against a prior period that included approximately $7.0 billion talc reserve reversal recorded in 2025 and stronger other income. Diluted EPS was $2.27 for the quarter and $4.41 for the six months.
Innovative Medicine generated $16,384 million in second‑quarter sales, led by oncology, neuroscience and strong growth from products such as DARZALEX, CARVYKTI and TREMFYA, while Immunology declined as STELARA faced erosion. MedTech sales were $8,926 million, with growth across cardiovascular, surgery, vision and orthopaedics; the MedTech segment absorbed $0.3 billion in Orthopaedics separation costs in the quarter.
Operating cash flows for the fiscal six months were robust at $11,130 million, supporting $6,358 million in dividends and $4,253 million of share repurchases. Cash and cash equivalents were $20,422 million and total shareholders’ equity was $84,971 million. The present value of the reserve for talc‑related matters was approximately $3.7 billion, about 40% classified as current, with roughly 76,000 U.S. plaintiffs; the company states that while individual periods may be affected, it does not expect these matters, net of accruals, to materially impact its overall financial position.
Strategically, J&J agreed to acquire Firefly Bio, Inc. for $1 billion in cash, expected to close in the fiscal third quarter of 2026, and entered a co‑funding agreement with Royalty Pharma plc for up to $0.5 billion through 2027 to support development of JNJ‑4804, with funding recognized as a reduction of research and development expense as services are performed.
Johnson & Johnson reported mixed results for the fiscal first quarter ended March 29, 2026. Sales to customers reached $24,062 million, up from $21,893 million, driven by 11.2% growth in Innovative Medicine and 7.7% in MedTech. Oncology, neuroscience and pulmonary hypertension therapies showed strong increases, while some immunology products such as STELARA and XARELTO in cardiovascular declined.
Profitability was much lower than a year ago. Net earnings were $5,235 million versus $10,999 million, and diluted EPS was $2.14 compared with $4.54. The prior year included a large benefit from reversing approximately $7.0 billion of talc reserve and significant other income; the current quarter includes about $0.3 billion of talc-related charges.
Operating cash flow was $2,514 million, down from $4,174 million, as payables and accrued liabilities decreased. The company returned cash through $3,131 million in dividends and $4,028 million of share repurchases, while cash and cash equivalents rose to $21,688 million. Total assets were $200,894 million and total liabilities $119,708 million, leaving shareholders’ equity at $81,186 million.
Johnson & Johnson reported significantly stronger results for the quarter and first nine months of 2025. Quarterly sales rose to $23.99 billion, up 6.8% from a year ago, with net earnings climbing to $5.15 billion versus $2.69 billion. Diluted EPS increased to $2.12 from $1.11.
For the first nine months, sales reached $69.63 billion, up 5.0%, while net earnings more than doubled to $21.69 billion, and diluted EPS rose to $8.94 from $4.38. Results benefited from a roughly $7 billion reversal of previously accrued talc reserves, partly offset by a higher effective tax rate of 21.5% following U.S. tax law changes.
The company closed the $14.5 billion acquisition of Intra-Cellular Therapies, adding CAPLYTA and a CNS pipeline to the Innovative Medicine segment. MedTech growth was supported by prior acquisitions such as Shockwave. As of October 17, 2025, there were 2,409,295,102 common shares outstanding.